Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics, Inc.

Beverly Hills Institute of Ophthalmology provides ophthalmology services including LASIK surgery, cataract surgery, and comprehensive eye care. The institute is described as having advanced technology and a team of experienced ophthalmologists.

Beverly Hills Institute of Ophthalmology

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Oxurion NV

Aldeyra Therapeutics, Inc. develops medications targeting immune-mediated and metabolic diseases.

Metric
Company Name	Aldeyra Therapeutics, Inc.	Beverly Hills Institute of Ophthalmology	Oxurion NV
Symbol	ALDX		OXUR
MSH ID	COM:ALDEYRA	COM:90210EYES	COM:OXURION
Market	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Medical Services	Biotechnology
Country	US	US	BE
Stage
Employee Count	10		20
Website	aldeyra.com	90210eyes.com	oxurion.com
LinkedIn
Founders

Metric
Market Cap	202.01M	2.59M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			277.79K
Revenue (LTM)
Revenue (NTM)
Gross Profit			109.85K
EBITDA			-14.24M
Operating Income			-12.79M
Net Income			-20.04M
EPS			-0.01
Diluted EPS			-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			-0.16
Operating Profit Margin			-32.84
EBITDA Margin			-51.27
Net Profit Margin			-54.03
Return on Equity			4.21
Return on Assets			-2.35
Return on Capital Employed			2.47

COM:ALDEYRA

Aldeyra Therapeutics, Inc.

Last Close

4.81

22/11 21:00

Market Cap

202.01M

Beta: -

Volume Today

652.02K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-0.00
P/B Ratio			-0.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			15.36
EV Multiple			1.55

Metric
Days Sales Outstanding
Days Payables Outstanding			3.59K
Days Inventory Outstanding			0.45
Operating Cycle			3.72K
Cash Conversion Cycle			479.87
Asset Turnover			0.08

Metric
Operating Cash Flow			-10.31M
Free Cash Flow			-10.32M
Cash Flow to Debt			-0.39
Operating Cash Flow/Sales			-17.83
Free Cash Flow Yield			-11.06

Metric
Cash & Equivalents			1.72M
Accounts Receivable			2.83M
Inventory			135.20K
Goodwill
Debt to Capitalization			6.89
Debt to Assets			0.67
Current Ratio			0.58
Quick Ratio			0.40

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			1.57
R&D to Revenue			26.87
SG&A to Revenue			7.45